Johnson–McMillin syndrome

From WikiMD's Wellness Encyclopedia

Autosomal dominant - en

Johnson–McMillin syndrome is a rare genetic disorder characterized by a combination of neurological and dermatological abnormalities. It is named after the researchers who first described the condition. The syndrome is primarily associated with mutations in the GJB2 gene, which encodes the protein connexin 26.

Clinical Features[edit | edit source]

Individuals with Johnson–McMillin syndrome typically present with a range of symptoms that can vary in severity. Common clinical features include:

Genetics[edit | edit source]

Johnson–McMillin syndrome is inherited in an autosomal dominant manner. This means that a single copy of the mutated gene is sufficient to cause the disorder. The GJB2 gene mutation leads to dysfunctional connexin 26 protein, which is crucial for the function of gap junctions in various tissues, including the skin and inner ear.

Diagnosis[edit | edit source]

The diagnosis of Johnson–McMillin syndrome is based on clinical evaluation, family history, and genetic testing. Audiometry is often used to assess the degree of hearing loss, while skin biopsies may be performed to examine the dermatological abnormalities. Genetic testing can confirm the presence of mutations in the GJB2 gene.

Management[edit | edit source]

There is currently no cure for Johnson–McMillin syndrome, and treatment is primarily supportive. Management strategies may include:

  • Hearing aids or cochlear implants for hearing loss
  • Topical treatments and emollients for skin conditions
  • Physical therapy for muscle weakness and neuropathy

Prognosis[edit | edit source]

The prognosis for individuals with Johnson–McMillin syndrome varies depending on the severity of symptoms. Early diagnosis and intervention can improve the quality of life for affected individuals.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]

-

Contributors: Prab R. Tumpati, MD